GlassScriptPhysician profile
Gabrielle Kec
NPI 1215306360
$2,745.96
in general payments reported to CMS, 2019-2025
26 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $489 · 2023: $344 · 2024: $663 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.76 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $387.94 | 2022-2025 | Rexulti, Abilify Maintena |
| Preventric Diagnostics, INC. | $347.98 | 2022 | |
| Axsome Therapeutics, INC. | $246.17 | 2024-2025 | Auvelity, Sunosi |
| Abbvie INC. | $237.41 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $236.10 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $177.11 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $136.73 | 2024-2025 | Azstarys |
| Neos Therapeutics, LP | $130.59 | 2024-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $115.87 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $105.39 | 2022-2025 | Spravato |
| Alkermes, INC. | $95.72 | 2024-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $95.70 | 2024-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $76.49 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $66.27 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $39.37 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.25 | 2022 | |
| Tempus Ai, INC | $34.52 | 2024 | |
| Smith+Nephew, INC. | $26.57 | 2021 | |
| Pfizer INC. | $25.71 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.45 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $22.66 | 2025 | Quviviq |
| Noven Therapeutics, LLC | $17.83 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $16.90 | 2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $16.69 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $15.02 | 2025 | Qelbree |
| Lucid Diagnostics INC. | $13.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Kec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.